Trial Profile
A Long-Term Open-Label Treatment and Extension Study of UX003 rhGUS Enzyme Replacement Therapy in Subjects With MPS 7
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Vestronidase alfa (Primary)
- Indications Mucopolysaccharidosis VII
- Focus Adverse reactions
- Sponsors Ultragenyx Pharmaceutical
- 16 Jan 2019 Status changed from active, no longer recruiting to completed.
- 01 Jun 2018 Planned End Date changed from 1 Feb 2019 to 1 Jan 2019.
- 01 Jun 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jan 2019.